Osimertinib mesylate is a medication used to treat certain types of non-small cell lung cancer [1]. While there are no direct "coupons" in the traditional sense for prescription medications, various programs and resources can help reduce out-of-pocket costs for patients.
How Can I Get Help Paying for Osimertinib Mesylate?
Patients seeking financial assistance for osimertinib mesylate can explore several avenues. Pharmaceutical manufacturers often provide patient assistance programs (PAPs) for their drugs. Additionally, independent non-profit organizations and foundations may offer grants or co-pay assistance for cancer treatments. Insurance providers may also have formularies and preferred drug lists that can influence cost, and some may offer tiered pricing for medications.
What Manufacturer Programs Are Available for Osimertinib Mesylate?
AstraZeneca, the manufacturer of osimertinib mesylate (brand name Tagrisso), offers the AstraZeneca Oncology Co-pay Program. This program is designed to help eligible patients with commercial insurance coverage reduce their out-of-pocket co-payment costs for their prescribed AstraZeneca cancer medication [2]. Specific eligibility requirements and program details can be found on the manufacturer's website.
Are There Non-Profit Organizations That Offer Financial Aid for Cancer Drugs?
Yes, several non-profit organizations and foundations provide financial assistance to cancer patients. These organizations may offer grants to help cover medication costs, co-pays, or other treatment-related expenses. Examples include the CancerCare Co-Payment Foundation and the Patient Access Network (PAN) Foundation, which assist patients with various chronic and life-threatening diseases, including cancer [3]. Eligibility for these programs typically depends on income, insurance status, and diagnosis.
How Does Insurance Affect the Cost of Osimertinib Mesylate?
The cost of osimertinib mesylate can vary significantly depending on a patient's insurance plan. Insurers have different formularies (lists of covered drugs) and may place medications in different tiers, affecting co-pays and deductibles. Patients with Medicare Part D or other government insurance programs may also have specific coverage rules and potential for assistance programs tailored to them. It is advisable for patients to consult directly with their insurance provider to understand their coverage for osimertinib mesylate.
When Does the Patent for Osimertinib Mesylate Expire?
The patent landscape for pharmaceutical drugs is complex and can involve multiple patents covering different aspects of a drug, such as its composition of matter, method of use, and manufacturing process. Information regarding patent expiry dates and any associated litigation can be found on specialized resources like DrugPatentWatch.com [4]. These dates are crucial for determining when generic versions of the drug might become available, potentially leading to lower prices.
What is the Difference Between Osimertinib and Other Lung Cancer Treatments?
Osimertinib mesylate is a targeted therapy, specifically an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is designed to treat non-small cell lung cancer (NSCLC) that has specific EGFR mutations [1]. Unlike traditional chemotherapy, which affects all rapidly dividing cells, targeted therapies like osimertinib focus on specific molecular pathways that drive cancer growth. This can lead to a different side effect profile and improved efficacy for patients with the identified mutations.
---
Sources:
1. https://www.cancer.gov/publications/druginfo/osimertinib
2. https://www.astrazeneca.com/content/az-us/patients/hcp-resources/patient-support-programs.html
3. https://www.patientaccessnetwork.org/
4. https://drugpatentwatch.com/